z-logo
Premium
Apoptosis and cellular proliferation in human epidermal squamous cell neoplasia
Author(s) -
Makino Takafumi,
Tatebe Shigeru,
Goto Akira,
Mihara Motoyuki,
Ito Hisao
Publication year - 1998
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.1600-0560.1998.tb01705.x
Subject(s) - tunel assay , pathology , immunohistochemistry , apoptosis , proliferating cell nuclear antigen , biology , proliferative index , ki 67 , terminal deoxynucleotidyl transferase , proliferation index , epidermis (zoology) , cell growth , cell , proliferation marker , cancer research , medicine , anatomy , biochemistry , genetics
We examined cell loss (apoptosis) and proliferation in a histopathological spectrum of epidermal squamous cell neoplasia, including 11 cases of solar keratosis (SK), 18 Bowen's diseases (BD) and 19 invasive squamous cell carcinomas (SCC). Apoptotic and proliferative cells were determined by terminal deoxynucleotidyl transferase (TdT)‐mediated dUTP‐digoxigenin nick end labeling (TUNEL) and by the detection of nuclear antigen Ki‐67, respectively. Few apoptotic cells were observed in normal epidermis, while TUNEL index (TI; percentage of TUNEL‐positive cells) was highest for SCCs, followed by BDs and SKs, in the order given. Although the mean Ki‐67 index did not differ between SCCs and BDs. both disease types showed a significantly higher index than the SKs. Of SCCs, both TI and Ki‐67 index values were significantly higher in poorly than in well differentiated carcinomas. TI was significantly higher in SCCs without P53 immunohistochemical expression than in SCCs with P53 expression, while TI and Ki‐67 indices did not correlate with P53 expression in the SKs and BDs. These results suggest that apoptosis reflects not only cell loss, but also proliferative activity in the epidermal neoplastic lesions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here